Fortis Healthcare Ltd. · NSE:FORTIS
Fortis Healthcare — Q2 FY27 Earnings Presentation
35 slides from Fortis Healthcare's earnings presentation, Nov 5, 2026
Slide 1: Regulation 30 filing cover letter to stock exchanges
Fortis Healthcare Limited Tower-A, Unitech Business Park, Block-F, South City 1, Sector – 41, Gurgaon, Haryana – 122 001 (India) Tel 0124 492 1033 Fax 0124 492 1041 Emergency 105010 Email: secretarial@fortishealthcare.com Website: www.fortishealthcare.com November 5, 2026 FHL/SEC/2026-27 The Nationa
Slide 2: Earnings Presentation – Q2 FY27 and H1 FY27
FORTIS HEALTHCARE LIMITED EARNINGS PRESENTATION – Q2 FY27 and H1 FY27 November 05, 2026 1
Slide 3: Disclaimer
DISCLAIMER This presentation may not be copied, published, distributed or transmitted. The presentation has been prepared solely by the company. Any reference in this presentation to “Fortis Healthcare Limited” shall mean, collectively, the Company and its subsidiaries. This presentation has been pr
Slide 4: About Fortis Healthcare
About Fortis Healthcare National Capital Region ➢ FMRI, Gurugram ➢ FEHI, New Delhi 37 Healthcare Facilities ➢ Shalimar Bagh 2,210 ➢ Noida Himachal Pradesh ➢ Vasant Kunj (O&M) ➢ Kangra (O&M) 81 ➢ Faridabad 6,300+ Operational Beds^ ➢ Manesar, Gurugram Punjab ➢ La Femme GK ➢ Mohali ➢ Def Col ➢ Ludhiana
Slide 5: Agenda
AGENDA 1. Performance Highlights • Earnings and Financial Summary – Q2FY27 and H1FY27 2. Performance Review - Hospital Business • Beds Expansion Strategy 3. Performance Review - Diagnostics Business 4. Clinical Excellence at Fortis 5. Appendix 4
Slide 6: Q2FY27 and H1FY27 Performance Highlights
Q2FY27 and H1FY27 PERFORMANCE HIGHLIGHTS 5
Slide 7: Q2FY27 Snapshot
Q2FY27 SNAPSHOT Consolidated Revenue Consolidated PBT1 Consolidated PAT1 2,735 Crores 429 Crores 317 Crores (11.6% Margin) 17.3% 6.8% 4.0% Net Debt / (Cash)3 Net Debt to EBITDA2,3 2,188 Crores 0.87x vs 0.96x 1. Excluding exceptional items 2. Basis Q2 annualized EBITDA 3. Net Debt as on 30th Septembe
Slide 8: H1FY27 Snapshot
H1FY27 SNAPSHOT Consolidated Revenue Consolidated PBT1 Consolidated PAT1 5,280 Crores 783 Crores 581 Crores (11.0% Margin) 17.4% 5.8% 3.8% Net Debt / (Cash)3 Net Debt to EBITDA2,3 2,188 Crores 0.87x vs 0.96x 1. Excluding exceptional items 2. Basis Q2 annualized EBITDA 3. Net Debt as on 30th Septembe
Slide 9: Recent Key Updates
Recent Key Updates Definitive Agreements to provide Healthcare services to a 400+ Bedded Hospital in Ashok Vihar, Delhi Sep’26: Fortis Healthcare, through its wholly owned subsidiary, entered into definitive agreements with Seth Sunder Lal Jain Charitable Eye Hospital to provide healthcare services
Slide 10: Q2FY27 Snapshot
Q2FY27 SNAPSHOT ➢ Hospital business revenues grew 18.6% to INR 2,340 Cr versus INR 1,974 Cr in Q2FY26 ➢ Hospital Business Profit After Tax* stood at INR 281 Cr, up by 6.6%; while PAT margin was at 12.0% versus 13.4% in Q2FY26. ➢ Q2FY27 hospital business ARPP^ was at INR 2.10 Lacs vs INR 1.96 Lacs in
Slide 11: Consolidated Earnings Summary – Q2FY27
CONSOLIDATED EARNINGS SUMMARY – Q2FY27 All figures in INR Cr Revenue PBT* 2,735 2,545 429 402 354 2,331 Q2FY26 Q1FY27 Q2FY27 Q2FY26 Q1FY27 Q2FY27 Up 17.3% Up 6.8% PAT* PAT Margin* 305 317 13.1% 263 10.3% 11.6% Q2FY26 Q1FY27 Q2FY27 Q2FY26 Q1FY27 Q2FY27 Up 4.0% *PBT, PAT and PAT Margin for Q2FY26, Q1F
Slide 12: Consolidated Earnings Summary – H1FY27
CONSOLIDATED EARNINGS SUMMARY – H1FY27 All figures in INR Cr Revenue PBT* 5,280 4,498 783 740 H1FY26 H1FY27 H1FY26 H1FY27 Up 17.4% Up 5.8% PAT* PAT Margin* 581 12.4% 559 11.0% H1FY26 H1FY27 H1FY26 H1FY27 Up 3.8% * PBT, PAT and PAT Margin for H1FY27 and H1FY26 PAT excludes exceptional gain of INR 12.
Slide 13: Consolidated Earnings Summary
CONSOLIDATED EARNINGS SUMMARY All figures in INR Cr Consolidated Revenue 2,735 2,365 2,545 2,331 2,265 Q2FY26 Q3FY26 Q4FY26 Q1FY27 Q2FY27 PAT Margin* PAT* PBT* 11.6% 13.1% 12.0% 10.3% 10.7% 450 429 402 400 354 337 350 312 317 305 300 284 263 243 250 200 Q2FY26 Q3FY26 Q4FY26 Q1FY27 Q2FY27 *PBT, PAT a
Slide 14: Hospital Business Highlights
Q2FY27 HOSPITAL BUSINESS HIGHLIGHTS Key Performance Indicators Overall Occupancy • Occupancy was at 72%, compared to 71% in Q2FY26. Occupied beds increased to 3,616 compared to 3,318 in 71% 72% 69% Q2FY26, a growth of 9%. • Revenue from focus specialties comprising Oncology, Neuro Sciences, Cardiac
Slide 15: Diagnostics Business Highlights
Q2FY27 DIAGNOSTICS BUSINESS HIGHLIGHTS • Agilus reported gross revenue of INR 448 Cr in Q2FY27 as compared to INR 400 Cr in Q2FY26, a growth of 12%. • PAT stood at INR 68 Cr in Q2FY27 versus INR 59 Cr in Q2FY26. • PAT Margin (basis gross revenues) stood at 15.2% versus 14.8% in Q2FY26. Gross Revenue
Slide 16: Operating Performance – Hospital Business
OPERATING PERFORMANCE HOSPITAL BUSINESS Hospital Business Particulars (INR Cr) Q2FY26 Q1FY27 Q2FY27 H1FY26 H1FY27 Operating Revenue 1,974 2,187 2,340 3,812 4,527 Revenue Growth vs LY 19.3% 19.0% 18.6% 19.0% 18.8% Operating EBITDA 452 471 545 858 1,016 Margin 22.9% 21.5% 23.3% 22.5% 22.4% Add: Other
Slide 17: Operating Performance – Diagnostics Business
OPERATING PERFORMANCE DIAGNOSTICS BUSINESS Diagnostics Business Particulars (INR Cr) Q2FY26 Q1FY27 Q2FY27 H1FY26 H1FY27 Operating Revenue 400 407 448 768 855 Revenue Growth vs LY 7.3% 10.2% 12.2% 7.3% 11.2% Operating EBITDA 104 97 118 189 215 Margin 26.1% 23.9% 26.2% 24.6% 25.1% Add: Other Income in
Slide 18: Balance Sheet (Consolidated)
BALANCE SHEET (CONSOLIDATED) September 30, 2026 Balance Sheet (INR Cr) Sep 30, 2025 Mar 31, 2026 Sep 30, 2026 Shareholder’s Equity 9,693 10,168 10,762 Debt 2,632 2,872 2,525 Lease Liabilities (Ind AS 116)* 562 600 640 Total Capital Employed 12,887 13,640 13,927 Net Fixed Assets (including intangible
Slide 19: Performance Review – Hospital Business
PERFORMANCE REVIEW HOSPITAL BUSINESS 18
Slide 20: Specialty Mix
SPECIALTY MIX Q2FY26 Q2FY27 Other Operating Other Operating Revenue, 1.6% Revenue, 1.6% Cardiac, Cardiac, OPD, 13.8% OPD, 14.4% 16.8% 16.1% Ortho, 8.3% Ortho, 9.1% Other IPD, Other IPD, 16.9% 17.2% Renal, 7.1% Renal, 7.5% Gynae, 3.3% Gynae, 3.1% Neuro, 8.2% Neuro, 8.8% Pulmo, 2.8% Pulmo, 3.4% Gastro
Slide 21: Payor Mix
PAYOR MIX Q2FY26 Q2FY27 TPAs, 36.3% TPAs, 37.1% Cash : Cash : Domestic, Domestic, 34.2% 34.2% Pvt Corps, 1.1% Pvt Corps, International , International , 1.2% 8.1% Govt & 7.7% Govt & PSUs, 8.4% CGHS, 4.3% ECHS, 7.5% PSUs, 8.0% CGHS, 5.1% ECHS, 6.7% 20
Slide 22: Hospital Business Performance – Q2FY27
HOSPITAL BUSINESS PERFORMANCE – Q2FY27 All geographical clusters continue to witness a YoY and QoQ upward momentum in revenues Net Revenue Cluster wise Q2 FY27 Q1 FY27 Q2 FY26 Operational Beds* Occupancy % (during Q2 FY27) (during Q2 FY27) 1,199 # Delhi NCR 1,132 2,300 72% 995 431 Punjab 406 1,017 7
Slide 23: Hospital Margin Matrix
HOSPITAL MARGIN MATRIX EBITDA* No of Facilities Revenue Contribution Operational beds ARPP# (INR Lacs) Occupancy >20% 15 84.3% 3,876 2.22 76% Q2FY27 15% - 20% 3 2.1% 134 1.54 55% 10% - 15% 4 9.6% 707 1.72 64% <10% 2^ 2.7% 276 1.36 54% * Operating EBITDA margin is Pre-ESOP expenses ^ Note: <10% EBITD
Slide 24: Beds Expansion Strategy
BEDS EXPANSION STRATEGY | | | |
Slide 25: Beds Expansion Strategy
BEDS EXPANSION STRATEGY O&M Beds – Gleneagles Fortis has an aspiration to reach ~12,000 beds over the next 3-5 years O&M Beds – Others Operational Beds ~ 2,200 ~ 12,000 ~ 1,600 ~400 ~ 1,900 ~1,200 ~ 6,300 ~1,200 ~500 ~700 ~5,100 Current Bed Brownfield O&M Inorganic Total Bed Capacity Expansion Expan
Slide 26: Performance Review – Diagnostics Business
PERFORMANCE REVIEW DIAGNOSTICS BUSINESS 25
Slide 27: Diagnostics Business
DIAGNOSTICS BUSINESS • During Q2FY27, Agilus conducted 11.39 Mn tests, versus 10.62 Mn in Q2FY26. • Agilus added ~300 Customer touchpoints* to its network in Q2FY27. Total CTPs as on 30th September 2026 stood at 4,551. • Agilus’ B2C: B2B revenue mix stood at 54:46 in the quarter vs 52:48 in Q2FY26.
Slide 28: Quarterly Revenue Mix
QUARTERLY REVENUE MIX Geographic mix Product Mix Segment Mix International 4% Wellness 15% Q2FY27 B2C, North 54% 30% South B2B, Routine 34% 46% 51% Specialised 34% East 12% West 19% International 4% Wellness 13% B2C, North 52% Q2FY26 30% South 33% Routine B2B, 53% 48% Specialised 34% East 12% West 2
Slide 29: Quarterly Key Performance Metrics
QUARTERLY KEY PERFORMANCE METRICS Test (mn) Avg. Realization per test (INR) No of Patients (mn) Avg. Realization per patient (INR) 4.80 980 11.5 400 395 4.70 960 390 4.60 11 393 952 958 940 385 4.50 387 380 4.40 920 10.5 922 375 4.30 900 375 375 370 4.20 903 10 900 369 365 4.10 880 878 363 360 4.00
Slide 30: Clinical Excellence at Fortis
CLINICAL EXCELLENCE AT FORTIS KEY HIGHLIGHTS 29
Slide 31: Clinical Excellence & Medical Programs
CLINICAL EXCELLENCE & MEDICAL PROGRAMS Clinical Excellence Augmenting Medical Programs ➢ Fortis Memorial Research Institute, Gurugram, ➢ Fortis Escorts, Okhla, New Delhi, inaugurated an successfully performed India’s first implantation of advanced Da Vinci Xi Robotic Surgical System, while the innov
Slide 32: Appendix
| x la Z uu Oo. oO. <x
Slide 33: Group Consolidated P&L – Q2FY27
GROUP CONSOLIDATED P&L – Q2FY27 Particulars ( INR Cr) Q2FY26 Q1FY27 Q2FY27 Revenue from operations 2,331.4 2,545.0 2,734.8 Other income 22.6 14.5 6.7 Total income 2,354.0 2,559.5 2,741.5 Expenses 1,775.1 2,007.9 2,111.6 EBITDA* 578.9 551.6 629.9 Margin 24.8% 21.7% 23.0% Finance costs 74.9 80.4 78.3
Slide 34: Group Consolidated P&L – H1FY27
GROUP CONSOLIDATED P&L – H1FY27 Particulars ( INR Cr) H1FY26 H1FY27 Revenue from operations 4,498.2 5,279.9 Other income 38.0 21.2 Total income 4,536.1 5,301.0 Expenses 3,451.2 4,119.6 EBITDA* 1,085.0 1,181.5 Margin 24.1% 22.4% Finance costs 144.4 158.7 Depreciation and amortisation expense 207.3 25
Slide 35: Thank You
THANK YOU 34